Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Interim CEO Cornelius Becomes Permanent Chief Exec

This article was originally published in The Pink Sheet Daily

Executive Summary

James Cornelius has delayed retirement to stay with the company as permanent CEO through early 2009.

You may also be interested in...



Bristol Restructures To Cut Costs, Transform Into Next-Generation Biopharma

Plan to achieve $1.5 billion in cost reductions by 2010 includes a 10 percent net reduction in head count.

Bristol Restructures To Cut Costs, Transform Into Next-Generation Biopharma

Plan to achieve $1.5 billion in cost reductions by 2010 includes a 10 percent net reduction in head count.

Ready, Set, Cut: Bristol Headcount Reductions Imminent

Drug maker will release details on its productivity initiative during an investor meeting Dec. 5.

Related Content

Topics

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel